FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311187356> ?p ?o ?g. }

• W4311187356 endingPage "1625" @default.
• W4311187356 startingPage "1610" @default.
• W4311187356 abstract "Abstract Myeloid neoplasms with erythroid or megakaryocytic differentiation include pure erythroid leukemia, myelodysplastic syndrome with erythroid features, and acute megakaryoblastic leukemia (FAB M7) and are characterized by poor prognosis and limited treatment options. Here, we investigate the drug sensitivity landscape of these rare malignancies. We show that acute myeloid leukemia (AML) cells with erythroid or megakaryocytic differentiation depend on the antiapoptotic protein B-cell lymphoma (BCL)-XL, rather than BCL-2, using combined ex vivo drug sensitivity testing, genetic perturbation, and transcriptomic profiling. High-throughput screening of &gt;500 compounds identified the BCL-XL–selective inhibitor A-1331852 and navitoclax as highly effective against erythroid/megakaryoblastic leukemia cell lines. In contrast, these AML subtypes were resistant to the BCL-2 inhibitor venetoclax, which is used clinically in the treatment of AML. Consistently, genome-scale CRISPR-Cas9 and RNAi screening data demonstrated the striking essentiality of BCL-XL-encoding BCL2L1 but not BCL2 or MCL1, for the survival of erythroid/megakaryoblastic leukemia cell lines. Single-cell and bulk transcriptomics of patient samples with erythroid and megakaryoblastic leukemias identified high BCL2L1 expression compared with other subtypes of AML and other hematological malignancies, where BCL2 and MCL1 were more prominent. BCL-XL inhibition effectively killed blasts in samples from patients with AML with erythroid or megakaryocytic differentiation ex vivo and reduced tumor burden in a mouse erythroleukemia xenograft model. Combining the BCL-XL inhibitor with the JAK inhibitor ruxolitinib showed synergistic and durable responses in cell lines. Our results suggest targeting BCL-XL as a potential therapy option in erythroid/megakaryoblastic leukemias and highlight an AML subgroup with potentially reduced sensitivity to venetoclax-based treatments." @default.
• W4311187356 created "2022-12-24" @default.
• W4311187356 creator A5007815385 @default.
• W4311187356 creator A5008868111 @default.
• W4311187356 creator A5010161935 @default.
• W4311187356 creator A5013364899 @default.
• W4311187356 creator A5017560855 @default.
• W4311187356 creator A5025335008 @default.
• W4311187356 creator A5026984704 @default.
• W4311187356 creator A5028974486 @default.
• W4311187356 creator A5031300613 @default.
• W4311187356 creator A5037129838 @default.
• W4311187356 creator A5040796609 @default.
• W4311187356 creator A5044105452 @default.
• W4311187356 creator A5050056974 @default.
• W4311187356 creator A5050873337 @default.
• W4311187356 creator A5058714222 @default.
• W4311187356 creator A5059091760 @default.
• W4311187356 creator A5061588223 @default.
• W4311187356 creator A5061939140 @default.
• W4311187356 creator A5063732976 @default.
• W4311187356 creator A5064764393 @default.
• W4311187356 creator A5065158992 @default.
• W4311187356 creator A5067760174 @default.
• W4311187356 creator A5074126248 @default.
• W4311187356 creator A5075652479 @default.
• W4311187356 creator A5087038443 @default.
• W4311187356 creator A5088386462 @default.
• W4311187356 creator A5089207174 @default.
• W4311187356 creator A5089248994 @default.
• W4311187356 creator A5090087937 @default.
• W4311187356 date "2023-03-30" @default.
• W4311187356 modified "2023-10-01" @default.
• W4311187356 title "Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia" @default.
• W4311187356 doi "https://doi.org/10.1182/blood.2021011094" @default.
• W4311187356 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36508699" @default.
• W4311187356 hasPublicationYear "2023" @default.
• W4311187356 type Work @default.
• W4311187356 citedByCount "11" @default.
• W4311187356 countsByYear W43111873562023 @default.
• W4311187356 crossrefType "journal-article" @default.
• W4311187356 hasAuthorship W4311187356A5007815385 @default.
• W4311187356 hasAuthorship W4311187356A5008868111 @default.
• W4311187356 hasAuthorship W4311187356A5010161935 @default.
• W4311187356 hasAuthorship W4311187356A5013364899 @default.
• W4311187356 hasAuthorship W4311187356A5017560855 @default.
• W4311187356 hasAuthorship W4311187356A5025335008 @default.
• W4311187356 hasAuthorship W4311187356A5026984704 @default.
• W4311187356 hasAuthorship W4311187356A5028974486 @default.
• W4311187356 hasAuthorship W4311187356A5031300613 @default.
• W4311187356 hasAuthorship W4311187356A5037129838 @default.
• W4311187356 hasAuthorship W4311187356A5040796609 @default.
• W4311187356 hasAuthorship W4311187356A5044105452 @default.
• W4311187356 hasAuthorship W4311187356A5050056974 @default.
• W4311187356 hasAuthorship W4311187356A5050873337 @default.
• W4311187356 hasAuthorship W4311187356A5058714222 @default.
• W4311187356 hasAuthorship W4311187356A5059091760 @default.
• W4311187356 hasAuthorship W4311187356A5061588223 @default.
• W4311187356 hasAuthorship W4311187356A5061939140 @default.
• W4311187356 hasAuthorship W4311187356A5063732976 @default.
• W4311187356 hasAuthorship W4311187356A5064764393 @default.
• W4311187356 hasAuthorship W4311187356A5065158992 @default.
• W4311187356 hasAuthorship W4311187356A5067760174 @default.
• W4311187356 hasAuthorship W4311187356A5074126248 @default.
• W4311187356 hasAuthorship W4311187356A5075652479 @default.
• W4311187356 hasAuthorship W4311187356A5087038443 @default.
• W4311187356 hasAuthorship W4311187356A5088386462 @default.
• W4311187356 hasAuthorship W4311187356A5089207174 @default.
• W4311187356 hasAuthorship W4311187356A5089248994 @default.
• W4311187356 hasAuthorship W4311187356A5090087937 @default.
• W4311187356 hasBestOaLocation W43111873561 @default.
• W4311187356 hasConcept C104317684 @default.
• W4311187356 hasConcept C127561419 @default.
• W4311187356 hasConcept C203014093 @default.
• W4311187356 hasConcept C2777938653 @default.
• W4311187356 hasConcept C2778041864 @default.
• W4311187356 hasConcept C2778461978 @default.
• W4311187356 hasConcept C2778729363 @default.
• W4311187356 hasConcept C2779176958 @default.
• W4311187356 hasConcept C2779282312 @default.
• W4311187356 hasConcept C2779675984 @default.
• W4311187356 hasConcept C2780007613 @default.
• W4311187356 hasConcept C2780817109 @default.
• W4311187356 hasConcept C502942594 @default.
• W4311187356 hasConcept C54355233 @default.
• W4311187356 hasConcept C71924100 @default.
• W4311187356 hasConcept C86803240 @default.
• W4311187356 hasConceptScore W4311187356C104317684 @default.
• W4311187356 hasConceptScore W4311187356C127561419 @default.
• W4311187356 hasConceptScore W4311187356C203014093 @default.
• W4311187356 hasConceptScore W4311187356C2777938653 @default.
• W4311187356 hasConceptScore W4311187356C2778041864 @default.
• W4311187356 hasConceptScore W4311187356C2778461978 @default.
• W4311187356 hasConceptScore W4311187356C2778729363 @default.
• W4311187356 hasConceptScore W4311187356C2779176958 @default.
• W4311187356 hasConceptScore W4311187356C2779282312 @default.
• W4311187356 hasConceptScore W4311187356C2779675984 @default.
• W4311187356 hasConceptScore W4311187356C2780007613 @default.

• next